Quote | Rani Therapeutics Holdings Inc. (NASDAQ:RANI)
Last: | $2.87 |
---|---|
Change Percent: | -0.35% |
Open: | $2.86 |
Close: | $2.87 |
High: | $2.99 |
Low: | $2.78 |
Volume: | 27,678 |
Last Trade Date Time: | 07/25/2024 03:00:00 am |
News | Rani Therapeutics Holdings Inc. (NASDAQ:RANI)
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a...
2024-06-24 07:12:15 ET More on Rani Therapeutics Rani Therapeutics reports Q1 results Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics Financial information for Rani Therapeutics Read the full a...
Message Board Posts | Rani Therapeutics Holdings Inc. (NASDAQ:RANI)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Rani Therapeutics Holdings Inc. Company Name:
RANI Stock Symbol:
NASDAQ Market:
Rani Therapeutics Holdings Inc. Website:
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a...
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and Pr...
2024-05-16 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...